The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France
Chloé Dimeglio, Jean–Michel Loubes, Benjamin Deporte, Martine Dubois, Justine Latour, Jean‐Michel Mansuy, Jacques Izopet
Abstract
A new virus, SARS-CoV-2, has spread world-wide since December 2019, probably affecting millions of people and killing thousands. Failure to anticipate the spread of the virus now seriously threatens many health systems. We have designed a model for predicting the evolution of the SARS-CoV-2 epidemic in France, which is based on seroprevalence and makes it possible to anticipate the deconfinement strategy.
Topics & Concepts
SeroprevalenceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakKey (lock)DeconfinementLatin AmericansProsperityVirusSars virusMedicineBiologyPolitical scienceImmunologyOutbreakLawEcologyAntibodyInfectious disease (medical specialty)DiseaseQuantum mechanicsPhysicsQuarkPathologySerologyCOVID-19 epidemiological studiesSARS-CoV-2 and COVID-19 ResearchViral Infections and Outbreaks Research